AcadeMab Selected for the 2026 "Taiwan–Berkeley Health Innovation Accelerator"!

TAIPEI, TAIWAN – AcadeMab Biomedical Inc. is proud to announce that we have been officially selected for the "2026 Taiwan–Berkeley Health Innovation Accelerator," a prestigious program jointly driven by the National Development Council (NDC), the UC Berkeley School of Public Health (UC Berkeley SPH), and the Development Center for Biotechnology (DCB). As one of only six companies selected nationwide this year, AcadeMab will represent the strength of Taiwan’s biotech innovation. In August, we will head to the United States for a three-month intensive residency to solidify our strategic deployment within the global healthcare innovation ecosystem.

Dual-Track Training: Precision Alignment with the U.S. Market 

Our selection underscores the international recognition of AcadeMab’s unique technical platforms in Antibody Therapeutics and mRNA Vaccine Development, as well as the high global expansion potential of our business model. 

The program's roadmap begins in April with a four-month domestic intensive training phase focused on strategic diagnostics, high-intensity negotiation workshops, and networking with local venture capital. Following this, AcadeMab will relocate to the UC Berkeley School of Public Health in August. There, we will engage directly with Silicon Valley-based venture capitalists, medical institutions, and biotech experts to refine our Go-to-Market Strategy for the U.S. market.

Core Pipeline Ready for Global Impact

AcadeMab is currently in a pivotal growth phase, bolstered by a highly competitive core pipeline:

• Antibody Therapeutic AM-928: Delivering innovative oncology solutions to address significant Unmet Medical Needs.
• Dengue mRNA Vaccine: Targeted at global tropical medicine and public health demands with strong technical differentiation.

Joining the Berkeley program marks a major milestone in our journey toward international clinical development and cross-border licensing. By standing on the shoulders of one of the world's leading academic institutions, we aim to optimize our fundraising strategies, build deep trust with potential global strategic partners, and significantly enhance our visibility in global capital markets.

About AcadeMab Biomedical Inc. 

We are a leading Taiwanese biotech startup dedicated to the strategy of "Platform-Driven Products, Product-Created Value." We specialize in the R&D of innovative antibody drugs and mRNA vaccines. Leveraging our exceptional translational medicine capabilities and international perspective, we focus on developing high-value clinical therapies to solve global health challenges and strengthen our influence within the international biomedical industry.